Oak Hill’s other Phase II candidate, OHB-101, is being investigated as a potential treatment for a range of autoimmune diseases. OHB-101, along with OHB-607, originally came under Takeda’s wing as part of its acquisition of Shire Pharmaceuticals in 2019. The therapy is a soluble recomb...